Controversies in T1 bladder Ca: Early cystectomy vs. TUR
The management of patients with T1 grade III bladder cancer remains controversial,and experts disagree on the timing of radical cystectomy. In this UrologyTimes point/counterpoint discussion, James Montie, MD, and Michael Droller,MD, debate the merits of early cystectomy versus transurethral resection(TUR) and associated therapy. Dr. Montie is professor of urologic oncologyand chairman, department of urology, University of Michigan, Ann Arbor.Dr. Droller is professor and chairman of the department of urology, MountSinai Medical Center, New York. UT Editorial Consultant Robert C. Flanigan,MD, professor and chairman, department of urology, Loyola University MedicalCenter, Maywood, IL, served as moderator of the discussion.
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.